The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml.
about
Micronutrients in Oncological InterventionManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchRelationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.Biochemical markers of bone turnover in benign paroxysmal positional vertigoEmphasizing the health benefits of vitamin D for those with neurodevelopmental disorders and intellectual disabilitiesIncorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan.Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A "Real-Life" StudyCharacteristics associated with bone mineral density responses to alendronate in men.Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with OsteoporosisInfluence of drugs on vitamin D and calcium metabolismContribution of vitamin D insufficiency to the pathogenesis of multiple sclerosisSilicon: a review of its potential role in the prevention and treatment of postmenopausal osteoporosisEffect of vitamin D status on pharmacological treatment efficiency: Impact on cost-effective management in medicine.Effect of vitamin D status on pharmacological treatment efficiency: Impact on cost-effective management in medicine.Vitamin D: Update 2013: From rickets prophylaxis to general preventive healthcareUse of calcium supplements, vitamin D supplements and specific osteoporosis drugs among French women aged 75-85 years: patterns of use and associated factors.Effects of Cholecalciferol vs Calcifediol on Total and Free 25-Hydroxyvitamin D and Parathyroid Hormone.Assessment criteria for vitamin D deficiency/insufficiency in Japan: proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral ReseZoledronate treatment has different effects in mouse strains with contrasting baseline bone mechanical phenotypes.Vitamin D and bone disease.The impact of dietary calcium intake and vitamin D status on the effects of zoledronate.Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03.Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study.Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study.Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults.
P2860
Q26764839-765D38FA-94C5-473D-A143-ACD71C557086Q26782621-CDFF60F5-B699-4D34-9B42-E0D86704EE08Q31145542-736189F8-D307-4CBE-A2E0-F5E81A460CB9Q33632710-06C571B5-6C1E-4D53-9DF9-A9774EAF1E58Q34465429-75B5B49B-0618-4EE0-9EAF-5B07B96822DCQ35092609-3238D192-6EF3-42FB-88F6-BEDDC9C6FBF6Q35739579-14E9256F-06F8-4538-91ED-B297A11C7594Q36029011-39E8CF0D-1F27-47F1-96CD-1D5A72A69F94Q36127563-7442282D-0172-4D04-8C97-6F91644EE92DQ36187610-F520AA1E-9D57-43EB-A7EB-E20768CC6EBAQ36638670-C89EFAC0-B743-4CFE-ACE0-24603B662128Q36898633-FCB3D59B-286A-42D2-8B5A-C6E7EC6C618CQ37170323-646A0E91-7E58-4495-A7DC-E4121C1F110FQ37499899-023AAF67-9018-44BA-B744-84CA76BA9385Q37538266-3436BB96-211C-444B-9BB0-C8166B1F569BQ38151572-60A00E69-825D-4880-AB91-60718DE8DFBDQ38758833-0164ED27-83DA-4AB3-8D9D-561A4A6D6691Q38791345-77C1B454-7BB2-4B09-802B-A4133C4A5CEEQ39579625-4F352E91-9C71-4062-89DC-DBF95E37B5EBQ43233968-53453E00-92BA-46F1-99C3-5D8E928839CEQ45760059-28645FB8-A6BC-4AF7-807B-8542BC9EC3DAQ46153653-D7874C4D-2131-4474-9A1A-96D4914A460BQ51219386-AF92D56C-BEEA-4783-96BF-6F526CE14580Q53559191-C5F6D6AB-FB2B-4E8D-943D-E778AC51F671Q54615209-A2315493-E04D-43E9-A241-00118F116801Q54965822-75F33B8D-88DA-4CE8-B763-91BE2E0B9607
P2860
The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 January 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The 25
@nl
The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml.
@en
type
label
The 25
@nl
The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml.
@en
prefLabel
The 25
@nl
The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml.
@en
P2093
P2860
P1476
The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml.
@en
P2093
P2860
P2888
P304
P356
10.1007/S00198-011-1868-7
P407
P577
2012-01-12T00:00:00Z